Screening for Advanced Heart Failure IN Stable ouTpatientS - The SAINTS Study
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- Diagnostic Test: Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization
- Registration Number
- NCT05299879
- Lead Sponsor
- Rigshospitalet, Denmark
- Brief Summary
The purpose of the Screening for Advanced heart failure IN stable ouTpatientS (SAINTS) study is to determine the prevalence of advanced heart failure (HF) in symptomatic patients with HF and reduced left ventricular ejection fraction (HFrEF), corresponding to the New York Heart Association functional class II-III.
Recognition of advanced HF is a challenge for physicians and under referral for advanced management is a considerable problem. There are excellent treatment options for patients with advanced HF, i.e. heart transplantation or left ventricular assist device (LVAD) implantation, and outcomes with these therapies are considerably better if patients are treated before irreversible end-organ damage occurs. International consensus highlights the importance of timely recognition and referral of these patients to advanced HF centers.
The investigators aim to screen patients with symptomatic HFrEF who are followed in Danish HF clinics in the Copenhagen region with echocardiography, cardiopulmonary exercise test, 6 minute walk test, and NT-proBNP. The investigators hypothesize that 20% of patients with symptomatic heart failure followed in HF clinics in the Copenhagen Region will fulfill the modified criteria for advanced HF from the HFA-ESC (primary end-point in the study)(Reference 1). Patients who are identified with advanced HF will be offered right heart catheterization, guided by ultrasound and inserted through the internal jugular vein, determining pulmonary capillary wedge pressure, cardiac index, central venous pressure, mean pulmonary artery pressure, and central venous oxygen saturation. Patients not fulfilling criteria for advanced HF will be offered right heart catheterization consecutively until 50 patients have been examined (this group will be a comparator group to the patients with advanced HF).
Patients identified with advanced HF will be offered listing for HTx or LVAD if an indication without a contraindication is present. Patients who fulfill the primary endpoint of modified HFA-ESC criteria for advanced HF, and are ineligible for, or unwilling to undergo HTx or LVAD implantation will be invited to participate in the SAINTS B study.
- Detailed Description
Number of patients and sample size More than 3000 patients are followed in the HF clinics on Zealand including the greater Copenhagen region. The investigators plan to include 400 patients in the primary outcome analysis (SAINTS A) and hypothesize that 20% will fulfill the modified criteria for advanced HF.
Statistical analysis Descriptive statistics will be reported as mean +/- standard deviation (SD) or median (interquartile range (IQR)) depending on distribution. Comparisons between groups at baseline will be performed by unpaired t-tests for normally distributed continuous variables, by the Mann-Whitney U test (Wilcoxon rank-sum) for non-normally distributed continuous variables and χ2 or Fisher's exact test for categorical variables.
The primary outcome will be analyzed as the proportion n (%) of included patients who fulfill the modified HFA-ESC criteria for advanced HF. As for secondary outcomes, the investigators will analyze the proportion n (%) of patients who within the first 3 months are; 1) offered heart transplant listing, 2) offered LVAD implantation, 3) listed for HTx and 4) undergoing LVAD implantation. Further, comparisons of invasive hemodynamics, CPET measures, 6MWT, QoL and NTproBNP levels between patients with and without advanced HF will be made using an unpaired t-test or the Mann-Whitney U test for non-normally distributed continuous variables.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 400
- History of Chronic heart failure > 3 months
- Stable (no hospitalization last 3 months) NYHA functional class II-III
- HFrEF patients (Left ventricular ejection fraction (LVEF) ≤ 30%)
- On or attempted betablocker and Renin-Angiotensin System (RAS) inhibitor treatment
- Informed consent
- Body Mass Index (BMI) > 40 kg/m2
- Chronic renal replacement therapy or estimated Glomerular Filtration Rate (eGFR) < 15 ml/min/1.73m2
- Cardiac Resynchronization Therapy (CRT) implantation < 3 months ago or planned CRT
- Severe primary valvular disease
- On waiting list for heart transplantation or referred for evaluation
- Cancer or other severe non-cardiac disease with estimated life expectancy less than 1 year
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Symptomatic patients with HFrEF corresponding to NYHA II-III Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization -
- Primary Outcome Measures
Name Time Method Proportion of patients screened who fulfill advanced HF criteria using a modified HFA-ESC definition At time of screening Modified HFA-ESC criteria for advanced HF defined as:
• LVEF ≤ 30% as estimated by echocardiography
AND
• Peak oxygen uptake (VO2peak) \< 12 ml/kg/min (14 if on betablocker) with a Respiratory Exchange Ratio (RER) \> 1.05 OR \< 50% expected for age and gender OR 6 minute walk test (6MWT) distance \< 300 meters
AND
• N-terminal pro B-type natriuretic peptide (NTproBNP) \> 2000 pg / ml
- Secondary Outcome Measures
Name Time Method Quality of Life (Kansas City Cardiomyopathy Questionnaire (KCCQ) At screening Proportion of patients offered LVAD implantation < 3 months after primary outcome 3 months after meeting modified HFA-ESC criteria for advanced HF Cardiac index (CI) in l/min/m2 compared between patients with, and without advanced HF Within 30 days from screening Measured during right heart catheterization
Peak oxygen uptake (VO2peak) in ml/kg/min compared between patients with, and without advanced HF At time of screening Measured during cardiopulmonary exercise test
6 minute walk test compared between patients with, and without advanced HF At screening Proportion of patients listed for heart transplantation < 3 months after primary outcome 3 months after meeting modified HFA-ESC criteria for advanced HF Proportion of patients undergoing LVAD implantation < 3 months after primary outcome 3 months after meeting modified HFA-ESC criteria for advanced HF Proportion of patients offered heart transplant listing < 3 months after primary outcome 3 months after meeting modified HFA-ESC criteria for advanced HF Pulmonary capillary wedge pressure (PCWP) in mmHg compared between patients with, and without advanced HF Within 30 days from screening Measured during right heart catheterization
Central venous pressure (CVP) in mmHg compared between patients with, and without advanced HF Within 30 days from screening Measured during right heart catheterization
Minute ventilation-to-carbon dioxide output slope (VE/VCO2) compared between patients with, and without advanced HF At time of screening The ratio between metabolic production of CO2 and the uptake of O2 measured during cardiopulmonary exercise test
Peak Borg scale score compared between patients with, and without advanced HF At time of screening The Borg scale score is a rating of perceived exertion on a scale from 6-20, with 6 representing at rest, and 20 the most strenuous exercise imaginable. Measured during cardiopulmonary exercise test
NT-proBNP compared between patients with, and without advanced HF At screening Mean pulmonary artery pressure (mPAP) in mmHg compared between patients with, and without advanced HF Within 30 days from screening Measured during right heart catheterization
Central venous oxygen saturation in % compared between patients with, and without advanced HF Within 30 days from screening Measured during right heart catheterization
Peak respiratory exhange ratio compared between patients with, and without advanced HF At time of screening The ratio between metabolic production of CO2 and the uptake of O2 measured during cardiopulmonary exercise test
Trial Locations
- Locations (6)
Zeeland University Hospital Roskilde
🇩🇰Roskilde, Denmark
Herlev and Gentofte Hospital
🇩🇰Copenhagen, Denmark
Bispebjerg-Frederiksberg Hospital
🇩🇰Copenhagen, Denmark
Glostrup Hospital
🇩🇰Glostrup, Denmark
Nordsjællands Hospital Hillerød
🇩🇰Hillerød, Denmark
Amager/Hvidovre Hospital
🇩🇰Copenhagen, Denmark